Expert Review of Vaccines

Papers
(The H4-Index of Expert Review of Vaccines is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?194
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States174
Parental category B vaccine hesitancy and associated factors in China: an online cross-sectional survey92
Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis92
Indirect protection from rotavirus vaccines: a systematic review88
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response80
Relationship between attitudes toward the effectiveness of vaccine, concerns about adverse reactions, and proactively taking SARS-Cov-2 vaccine for family among medical workers in Taizhou, China73
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant 64
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy62
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic60
Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings59
The important lessons lurking in the history of meningococcal epidemiology59
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era58
Effectiveness of maternal vaccination with quadrivalent inactivated influenza vaccine in pregnant women and their infants in 2019-202056
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China55
COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis52
Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness49
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumo44
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children44
Personal and contextual determinants of COVID-19 vaccination intention: a vignette study43
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays41
Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment39
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis38
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review37
Microarray patches: scratching the surface of vaccine delivery36
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection36
Who is more likely to hesitate to accept COVID-19 vaccine: a cross-sectional survey in China35
Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women35
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis35
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom35
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above34
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond33
Vaccines against leishmaniasis: using controlled human infection models to accelerate development33
Parental COVID-19 vaccine hesitancy: a cross-sectional survey in Italy33
0.14272999763489